Cancer Vaccine R&D Makes Strides With Better Endpoints, Patient Selection
Executive Summary
As cancer vaccine and immunotherapy developers try to get past the difficulties of recent years, they are looking to improve their chances for success by identifying the correct cancer types and settings to best respond to a specific vaccine and then choosing more meaningful endpoints for clinical trials
You may also be interested in...
Cancer Vaccine Makers Capitalize On Provenge Fanfare At ASCO
Heading into this year's American Society of Clinical Oncology meeting, beleaguered cancer immunotherapy developers finally have some cause for optimism about potential partnerships and, battle-hardened, they say they are hearty enough to wait for deals to roll in
Cancer Vaccine Makers Capitalize On Provenge Fanfare At ASCO
Heading into this year's American Society of Clinical Oncology meeting, beleaguered cancer immunotherapy developers finally have some cause for optimism about potential partnerships and, battle-hardened, they say they are hearty enough to wait for deals to roll in
The Endgame on Oncology Endpoints
The annual ASCO meeting, held in Chicago this year, provided a forum for investigators to discuss the merits of continued use of progression-free survival as an endpoint in oncology clinical trials. Phase III data from Roche/Genentech's Avastin in metastatic breast cancer sparked debate.